Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Last trade$0.4982
Day change+$0.0624 (+14.32%)
Day range$0.41 – $0.554
Volume4,264,992
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.94M
Price / earnings
—
Price / book
0.63×
Price / sales
0.68×
EV / sales
-0.49×
EV / EBITDA
0.25×
Profitability
Earnings per share
-$3.17
Return on assets
-111.51%
Return on equity
-450.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.49×
Quick ratio
0.49×
Cash ratio
0.37×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.59M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRIS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$1.14M
$3.18M
$2.75M
$2.38M
$3.35M
$2.93M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$1.14M
$3.18M
$2.75M
$2.38M
$3.35M
$2.93M
Selling, general and administrative
$3.23M
$5.07M
$2.88M
$3.65M
$3.53M
$3.98M
$3.35M
$3.75M
Research and development
$6.71M
$6.45M
$5.83M
$6.43M
$7.46M
$8.54M
$8.97M
$9.72M
Total operating expenses
$9.94M
$11.52M
-$18.48M
$10.1M
$11M
$12.54M
$12.34M
$13.5M
Operating income
-$9.94M
-$11.52M
$19.62M
-$6.92M
-$8.25M
-$10.16M
-$8.99M
-$10.57M
Interest expense
$0
$0
-$314K
-$885K
-$434K
-$552K
-$851K
$150K
Income before taxes
-$8.58M
-$24.2M
$19.36M
-$7.73M
-$8.59M
-$10.62M
-$9.62M
-$10.09M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.58M
-$24.2M
$19.36M
-$7.73M
-$8.59M
-$10.62M
-$9.62M
-$10.09M
Net income attributable to common shareholders
-$8.58M
-$24.2M
$19.36M
-$7.73M
-$8.59M
-$10.62M
-$9.62M
-$10.09M
EBITDA
-$9.93M
-$11.51M
$19.66M
-$6.89M
-$8.21M
-$10.1M
-$8.98M
-$10.51M
Basic earnings per share
-$4.02
-$25.00
$24.42
-$9.80
-$13.61
-$25.00
-$25.04
-$34.00
Diluted earnings per share
-$4.02
-$25.00
$24.42
-$9.80
-$13.61
-$25.00
-$25.04
-$34.00
Recent news
Company coverage with links to the original publishers.
Curis reported Q3 2026 results highlighting progress on its lead oncology program emavusertib. The company announced an 86% response rate in BTK-naive patients with PCNSL (compared to 39-67% for BTK inhibitor monotherapy alone) and a 26% response rate in salvage-line patients. A CLL study was initiated with 12 patients enrolled across 11 sites, with initial data expected by year-end. The company reported a net loss of $8.1 million for Q3 2026 and $5 million in cash, with runway into 2027. Full enrollment in the PCNSL registrational study is expected by end of 2027, with NDA filing anticipated in 2028.
Lift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.
Curis reported Q4 2025 net income of $19.4 million ($1.23 per share) driven by a $27.2 million one-time gain from selling Erivedge to Oberland. The company has eliminated legacy revenue streams and is now focused on advancing its TakeAim Lymphoma (PCNSL) registrational study and initiating a CLL proof-of-concept study. With $20.2 million in PIPE financing received in January 2026 and potential additional $20.2 million upon CLL milestone achievement, the company expects to fund operations into 2027. Early AML triplet therapy data showed five of eight evaluable patients achieved MRD conversion.
Biotechnology company Curis reported a narrowed Q2 2025 net loss of $0.68 per share, beating analyst expectations. The company continues advancing its cancer therapy emavusertib while facing near-term funding challenges, with cash reserves expected to last only into Q1 2026.
VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from existing therapies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.